We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-1.15%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.35B
AUM Growth
-$748M
Cap. Flow
-$582M
Cap. Flow %
-24.75%
Top 10 Hldgs %
32.94%
Holding
108
New
18
Increased
28
Reduced
25
Closed
23

Top Buys

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$43.9M
2
CGEM icon
Cullinan Oncology
CGEM
+$33.2M
3
INCY icon
Incyte
INCY
+$30M
4
TMO icon
Thermo Fisher Scientific
TMO
+$24.9M
5
ARGX icon
argenx
ARGX
+$23.2M

Top Sells

Rank Stock Value
1
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$139M
2
ALGN icon
Align Technology
ALGN
+$62M
3
BSX icon
Boston Scientific
BSX
+$57.5M
4
LLY icon
Eli Lilly
LLY
+$54.5M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$46.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.8%
2 Technology 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COLL icon
76
Collegium Pharmaceutical
COLL
$1.16B
$3.77M 0.16%
117,000
-244,400
-68% -$8.47M
PRME icon
77
Prime Medicine
PRME
$560M
$3.57M 0.15%
694,000
-1,296,000
-65% -$7.86M
ACIU icon
78
AC Immune
ACIU
$235M
$3.29M 0.14%
825,000
-3,645,000
-82% -$12.1M
KZR
79
DELISTED
Kezar Life Sciences
KZR
$3.02M 0.13%
502,600
– –
SCYX icon
80
SCYNEXIS
SCYX
$36.2M
$2.9M 0.12%
181,091
– –
KPTI icon
81
Karyopharm Therapeutics
KPTI
$166M
$1.75M 0.07%
134,567
-418,671
-76% -$6.93M
WVE icon
82
Wave Life Sciences
WVE
$1.15B
$1.75M 0.07%
+350,000
New +$2M
HYPR icon
83
Hyperfine
HYPR
$95.6M
$1.01M 0.04%
1,188,178
– –
CMAX
84
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$59.1K ﹤0.01%
21,200
– –
NUVB.WS
85
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$1.94K ﹤0.01%
12,136
-77,407
-86% -$15.8K
ACAD icon
86
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-588,500
Closed -$10.9M
ALGN icon
87
Align Technology
ALGN
$12.2B
– –
-189,000
Closed -$62M
ANTX icon
88
AN2 Therapeutics
ANTX
$180M
– –
-1,150,000
Closed -$3.74M
ATXS
89
DELISTED
Astria Therapeutics
ATXS
– –
-982,000
Closed -$13.8M
CRBU icon
90
Caribou Biosciences
CRBU
$161M
– –
-5,785,352
Closed -$29.7M
CVS icon
91
CVS Health
CVS
$136B
– –
-545,000
Closed -$43.5M
CYTK icon
92
CALL
Cytokinetics
CYTK
$11B
– –
-600,000
Closed -$42.1M
CYTK icon
93
Cytokinetics
CYTK
$11B
– –
-166,000
Closed -$11.6M
DNA icon
94
Ginkgo Bioworks
DNA
$490M
– –
-75,000
Closed -$3.48M
EBS icon
95
Emergent Biosolutions
EBS
$383M
– –
-1,908,000
Closed -$4.83M
GPCR icon
96
CALL
Structure Therapeutics
GPCR
$3.54B
– –
-150,000
Closed -$6.43M
IPSC icon
97
Century Therapeutics
IPSC
$384M
– –
-1,221,555
Closed -$5.11M
KOD icon
98
Kodiak Sciences
KOD
$2.67B
– –
-300,000
Closed -$1.58M
LLY icon
99
Eli Lilly
LLY
$1.07T
– –
-70,000
Closed -$54.5M
MCK icon
100
McKesson
MCK
$99.9B
– –
-33,300
Closed -$17.9M
1 2 3
4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q2 2024 Portfolio in Review

As of Q2 2024, Avidity Partners Management held 108 positions worth $2.35B, down 24% from $3.1B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $582M in Q2 2024, closing 23 positions and reducing 25 holdings. Its most notable exit was Fusion Pharmaceuticals Inc. Common Shares, an estimated $139M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier, followed by Technology.

Against the trend, Avidity Partners Management opened a new position in Perspective Therapeutics worth $30.3M.

  • Avidity Partners Management's largest Q2 2024 buy was Perspective Therapeutics: 3,037,668 shares worth $30.3M.
  • Avidity Partners Management added most to Thermo Fisher Scientific in Q2 2024, an estimated $24.9M increase.
  • Avidity Partners Management's biggest Q2 2024 reduction was Boston Scientific, cutting an estimated $57.5M.
  • Avidity Partners Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $139M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $2.35B portfolio in Q2 2024.
  • Avidity Partners Management opened 18 new positions and closed 23 in Q2 2024.
  • Avidity Partners Management's portfolio value fell 24% quarter-over-quarter to $2.35B.

Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.